Abdurrahman Işıkdoğan

Author

Also Known As

A Isikdogan, A Isıkdogan, A Işıkdoğan, A. ISIKDOGAN, A. Isikdogan, A. Isıkdogan, A. Işıkdoğan, ABDURRAHMAN ISIKDOGAN, Abdurrahman ISIKDOGAN, Abdurrahman ISİKDOGAN

279

Publications

Citations

H-Index

Concepts

All Affiliations

Dicle University Erciyes University Gaziantep University Gazi University Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi

About

Abdurrahman Işıkdoğan is an author at Dicle University specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	21	564
2	Health Sciences	3	3	136
3	Public Health	2	2	27
4	Diabetes	1	1	64
5	Epidemiology	1	1	13

Abdurrahman Işıkdoğan

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer Hakan Akbulut, Güngör Utkan, Bülent Yalçın, Journal of Surgical Oncology	2006	107
Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients Ayşe Durnalı, Şengül Cangür, Fisun Ardıç Yükrük, Medical Oncology Prognostic FactorsAdult PatientsHigh-grade OsteosarcomaOncologyRadiation Oncology	2013	79
Type 2 diabetes mellitus and prognosis in early stage breast cancer women Zafer Pekkolay, Mehmet Küçüköner, Ali̇ İnal, Medical Oncology Breast OncologyMedicineDiabetesPathologyBreast Cancer	2011	64
Outcome of non-metastatic male breast cancer: 118 patients Ülkü Yalçıntaş Arslan, Berna Öksüzoğlu, Nuriye Özdemir, Medical Oncology Surgical OncologyBreast OncologyMedicineCancer ManagementBreast Cancer	2011	61
Prognostic factors and clinical outcome of patients with Ewing’s sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology Erkan Arpacı, Tarkan Yetişyiğit, Metin Şeker, Medical Oncology Prognostic FactorsSurgical OncologyTumoral PathologyMulticentric StudyMalignant Disease	2013	51
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients Joseph Gligorov, Beyhan Ataseven, Mark Verrill, European Journal of Cancer Breast OncologyMedicinePrimary AnalysisAdjuvant TreatmentBreast Cancer	2017	46
Medication Errors in Chemotherapy Preparation and Administration: a Survey Conducted among Oncology Nurses in Turkey Arife Ulaş, Didem Şener Dede, Muhammed Bülent Akıncı, Asian Pacific Journal of Cancer Prevention	2015	45
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology Abdurrahman Işıkdoğan, Doğan Koca, Mehmet Küçüköner, Breast Cancer Breast OncologyCapecitabine Combination TherapyMedicineBrain MetastasisClinical Outcomes	2013	38
Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial) Nuri Faruk Aykan, Suayib Yalcin, Nazım Serdar Turhal, The Turkish Journal of Gastroenterology	2015	34
Childhood, Adolescents, and Young Adults (≤25 y) Colorectal Cancer Abdurrahman Işıkdoğan, Mahmut Gümüş, Ülkü Yalçıntaş Arslan, Journal of Pediatric Hematology/Oncology	2013	33

Page 1